David Taggart

Showing 1-12 of 12 articles

Prognostic performance of the Society of Thoracic Surgeons risk score in patients with left main coronary artery disease undergoing revascularisation: a post hoc analysis of the EXCEL trial

Thuijs D, Habib R, Head S, Puskas J, Taggart D, Stone G, Zhang Z, Serruys P, Sabik J, Kappetein A

May 20, 2020 | 10.4244/EIJ-D-19-00417

FFR for CABG: not ready for prime time

Gaudino M, Di Franco A, Taggart D

December 6, 2019 | 10.4244/EIJV15I11A177

Does an occluded RCA affect prognosis in patients undergoing PCI or CABG for left main coronary artery disease? Analysis from the EXCEL trial

Chen S, Karmpaliotis D, Redfors B, Shlofmitz E, Ben-Yehuda O, Crowley A, Mehdipoor G, Puskas J, Kandzari D, Banning A, Morice M, Taggart D, Sabik J, Serruys P, Kappetein A, Stone G

August 9, 2019 | 10.4244/EIJ-D-19-00263

Absence of proof or proof of absence? The risk of underpowered studies in cardiovascular medicine

Gaudino M, Benedetto U, Taggart D

September 20, 2018 | 10.4244/EIJV14I7A126

What is new in the armamentarium of coronary surgeons to compete with PCI?

Gaudino M, Taggart D

July 20, 2018 | 10.4244/EIJV14I4A69

Coronary interventions

Design and rationale for a randomised comparison of everolimus-eluting stents and coronary artery bypass graft surgery in selected patients with left main coronary artery disease: the EXCEL trial

Kappetein A, Serruys P, Sabik J, Leon M, Taggart D, Morice M, Gersh B, Pocock S, Cohen D, Wallentin L, Ben-Yehuda O, Van Es G-A, Simonton C, Stone G

September 18, 2016 | 10.4244/EIJV12I7A141

Coronary interventions

Rationale and design of the SYNTAX II trial evaluating the short to long-term outcomes of state-of-the-art percutaneous coronary revascularisation in patients with de novo three-vessel disease

Escaned J, Banning A, Farooq V, Echavarría-Pinto M, Onuma Y, Ryan N, Cavalcante R, Campos C, Stanetic B, Ishibashi Y, Suwannasom P, Kappetein A, Taggart D, Morel M, Van Es G-A, Serruys P

June 10, 2016 | 10.4244/EIJV12I2A36

2014 ESC/EACTS Guidelines on myocardial revascularization

Windecker S, Kolh P, Alfonso F, Collet J, Cremer J, Falk V, Filippatos G, Hamm C, Head S, Jüni P, Kappetein A, Kastrati A, Knuuti J, Landmesser U, Laufer G, Neumann F, Richter D, Schauerte P, Uva M, Stefanini G, Taggart D, Torracca L, Valgimigli M, Wijns W, Witkowski A

January 22, 2015 | 10.4244/EIJY14M09_01

Numbers needed to treat (lives!) and numbers needed to save (money)

Ribichini F, Taggart D, Vassanelli C

June 28, 2013 | 10.4244/EIJV9I2A28

Does a hybrid approach to multivessel revascularisation really make sense?

Taggart D

March 22, 2013 | 10.4244/EIJV8I11A189

Does prior PCI influence the clinical outcome of CABG?

Taggart D

May 19, 2009

Drug eluting stents in left main stem stenosis: patients will pay the price

Taggart D

February 20, 2007

Latest news

NEW ISSUE

Infective Endocarditis & TAVI; Cerebral Protection Devices; IVUS Assessment in ViV-TAVI, Mini Focus on Antithrombotic Therapy …

February 19, 2021

News

Don’t Miss #EIJOnAir 2nd Edition!

Elective cardiac invasive procedures during the COVID-19 outbreak

March 4, 2021

Ahead of Print

MitraClip for a range of LV dysfunction and secondary MR

Stamatios Lerakis et al.

March 2, 2021

Editorial

Thrombolysis in ST-elevation myocardial infarction is not dead

Petr Kala et al.

March 2, 2021

SCOPE 2, COACT 1 year, FORZA, COMPARE CRUSH

(Thanks to the support of Biotronik)

February 28, 2021

JAA

This Week's JAA's: Impact of crossing strategy on CTO recanalisation outcomes and more...

March 2, 2021

Guidance Papers

Guidelines, consensus & position papers